CME/CE

Use the tool below to view all available AXISMedEd Activities

Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
CME/CE
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
0.50 credits
- Carlos M. de Castro, MD
0.50 credits
Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
CME/CE
Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
0.25 credits
- Aditya Bardia, MD, MPH
0.25 credits
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
CME/CE
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
0.25 credits
- Tycel Phillips, MD
0.25 credits
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CE
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
0.25 credits
- Jorge E. Cortes, MD
0.25 credits
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
CME/CE
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
0.25 credits
- Mark Socinski, MD
0.25 credits
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CE
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
0.50 credits
- Sagar Lonial, MD, FACP
- Meghan Berkenstock, MD
- Saad Z. Usmani, MD, MBA, FACP
0.50 credits
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CE
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
0.25 credits
- Sara M. Tolaney, MD, MPH
0.25 credits
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
CME/CE
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
0.50 credits
- Adam Brufsky, MD, PhD
0.50 credits
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
CME/CE
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
0.50 credits
- Helena Yu, MD
0.50 credits
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
CME/CE
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
0.50 credits
- Matthew S. Davids, MD, MMSc
0.50 credits
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
CME/CE
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
0.50 credits
- Joshua E. Reuss, MD
0.50 credits
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned
Oncology and Hematology
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned
- Joseph Kim, MD, MPH
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CME/CE
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
0.50 credits
- Matthew Lunning, DO, FACP
0.50 credits

CME/CE

Popular

Title

Share on ReachMD